The gross proceeds to the Company from the exercise of the Existing Warrants together with the sale of the new warrants is expected to be approximately $6.2 million. The closing of the transaction is ...

Funding for the study was provided by Merck Sharp & Dohme. Van Gorp reported various relationships with AbbVie, AstraZeneca, Amgen, BioNTech, Eisai, GSK, ImmunoGen, Incyte, Karyopharm Therapeutics, ...

We anticipate a profitable buying opportunity for investors in Merck stock following a 15% decline in July. See why we ...

Current INSTI vs protease inhibitor or NNRTI use is linked to an increased risk for diabetes, which is slightly attenuated when adjusted for changes in BMI.

Gefapixant decreased cough-induced stress urinary incontinence (CSUI) episodes in women with refractory/unexplained chronic cough and CSUI.

Neoadjuvant therapy is an essential part of high-risk stage III resectable melanoma management, with combination ...

A statistically significant improvement in progression-free survival and objective response rate was seen with belzutifan ...

By week 56, kids, ages 6 to <12 years, on once-daily 3-mg liraglutide lost 5.8% of BMI compared with a 1.6% gain with ...

After Summit Therapeutics (NASDAQ:SMMT) said early this week that its lead asset ivonescimab outperformed Merck's (NYSE:MRK) ...

PD-1 inhibition before and after surgery for high-risk early triple-negative breast cancer (TNBC) led to significant ...

Results delivered in prestigious Proffered Paper oral presentation at ESMO Congress 2024 In patients with any PD-L1 ...

Keytruda shows promise as a first line option in cervical cancer cutting patients' mortality risk by a third in a Phase 3 ...